AMWL

Amwell is a chronic money-loser in the middle of a painful reset. FY2025 revenue of $249M fell 2.0% YoY — the fourth straight year of stagnation-to-decline from the $277M FY2022 peak — and the underlying operating metrics are worse than the headline: the MD&A shows average health-system clients dropping from 129 (2023) to 107 (2024) to 88 (2025), with total health-system subscription revenue falling from $53.5M to $52.0M to $40.6M. That is the core recurring business shrinking ~22% in a year, which is the single most damning fact in the filing. Cumulative destruction is enormous: a -$2.06B accumulated deficit against just $236M of equity.

The offsetting case is real and keeps this off the sell/avoid line. Losses are narrowing fast: net loss improved 54% to -$95.7M, operating loss improved 51.6% to -$105M, and operating cash burn improved 48.2% to -$66M as management divested the APC/telepsychiatry business (for $20.7M upfront) and unwound the Cleveland Clinic JV to concentrate on the Amwell Platform and 'the path to profitability.' The balance sheet is clean — $76M total liabilities against $236M equity (0.32x), no meaningful debt — and, most notably, $182M of cash exceeds the entire $152M market cap. You are effectively buying the operating business for a negative enterprise value with ~$11/share of cash behind a $9.25 stock.